{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T22:37:13Z","timestamp":1788820633392,"version":"build-2803163510"},"reference-count":37,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Advances in the treatment of Langerhans cell histiocytosis (LCH) have resulted in a growing survivor population. There is a lack of data on long-term outcomes among adults with LCH. We conducted a retrospective record review of 219 adults (aged \u226518 years) with LCH. Most common presentation was multisystem (34.2%), followed by single-system pulmonary (32%), unifocal (28.3%), and single-system multifocal (5.5%) LCH. Risk organ involvement (the liver, spleen, or bone marrow) was seen in 8.7% of cases, and 40 of 88 (45.5%) tested cases were BRAFV600E. At a median follow-up of 74\u00a0months, 5-year progression-free survival (PFS) was 58.3% and estimated median PFS was 83\u00a0months. Median overall survival (OS) was not reached; 5- and 10-year OS rates were 88.7% and 74.5%, respectively. Risk organ involvement was associated with worse PFS (hazard ratio [HR], 4.5) and OS (HR, 10.8). BRAFV600E was not associated with risk organ involvement or survival. When compared with matched unaffected US population, individuals with LCH had a significantly higher risk of overall mortality (standardized mortality ratio [SMR], 2.66), specifically among those aged &amp;lt;55 years at diagnosis (SMR, 5.94) and those with multisystem disease (SMR, 4.12). Second cancers occurred in 16.4% cases, including diverse hematologic and solid organ malignancies. LCH-associated deaths constituted 36.1% of deaths and occurred within 5 years of diagnosis. After 5 years, non-LCH causes of death, including second cancers, chronic obstructive pulmonary disease, and cardiovascular diseases, predominated. Our study highlights, to our knowledge, for the first time, that adults with LCH experience early and late mortality from non-LCH causes and the need for development of targeted survivorship programs to improve outcomes.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023010706","type":"journal-article","created":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T13:14:30Z","timestamp":1694524470000},"page":"6568-6578","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":27,"title":["Long-term outcomes among adults with Langerhans cell histiocytosis"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6148-5177","authenticated-orcid":false,"given":"Gaurav","family":"Goyal","sequence":"first","affiliation":[{"name":"1Division of Hematology-Oncology, University of Alabama at Birmingham, Birmingham, AL"},{"name":"2Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9414-9153","authenticated-orcid":false,"given":"Aldo A.","family":"Acosta-Medina","sequence":"additional","affiliation":[{"name":"3Department of Internal Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jithma P.","family":"Abeykoon","sequence":"additional","affiliation":[{"name":"4Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Dai","sequence":"additional","affiliation":[{"name":"5Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4503-440X","authenticated-orcid":false,"given":"Aishwarya","family":"Ravindran","sequence":"additional","affiliation":[{"name":"6Department of Pathology, University of Alabama at Birmingham, Birmingham AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Vassallo","sequence":"additional","affiliation":[{"name":"7Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9576-2272","authenticated-orcid":false,"given":"Jay H.","family":"Ryu","sequence":"additional","affiliation":[{"name":"7Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5359-336X","authenticated-orcid":false,"given":"Mithun V.","family":"Shah","sequence":"additional","affiliation":[{"name":"4Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8358-5953","authenticated-orcid":false,"given":"N. Nora","family":"Bennani","sequence":"additional","affiliation":[{"name":"4Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason R.","family":"Young","sequence":"additional","affiliation":[{"name":"8Department of Radiology, Mayo Clinic, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrie R.","family":"Bach","sequence":"additional","affiliation":[{"name":"9Department of Radiology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6969-9169","authenticated-orcid":false,"given":"Gordon J.","family":"Ruan","sequence":"additional","affiliation":[{"name":"4Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Zanwar","sequence":"additional","affiliation":[{"name":"4Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8141-2394","authenticated-orcid":false,"given":"W. Oliver","family":"Tobin","sequence":"additional","affiliation":[{"name":"10Department of Neurology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Koster","sequence":"additional","affiliation":[{"name":"11Division of Rheumatology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline J.","family":"Davidge-Pitts","sequence":"additional","affiliation":[{"name":"12Division of Endocrinology, Diabetes, and Nutrition, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucinda M.","family":"Gruber","sequence":"additional","affiliation":[{"name":"12Division of Endocrinology, Diabetes, and Nutrition, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surendra","family":"Dasari","sequence":"additional","affiliation":[{"name":"13Division of Biomedical Statistics and Informatics, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen L.","family":"Rech","sequence":"additional","affiliation":[{"name":"14Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald S.","family":"Go","sequence":"additional","affiliation":[{"name":"4Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,10,30]]},"reference":[{"issue":"17","key":"2023111414505481600_bib1","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1182\/blood.2021014343","article-title":"International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults","volume":"139","author":"Goyal","year":"2022","journal-title":"Blood"},{"issue":"11","key":"2023111414505481600_bib2","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood-2010-04-279083","article-title":"Recurrent BRAF mutations in Langerhans cell histiocytosis","volume":"116","author":"Badalian-Very","year":"2010","journal-title":"Blood"},{"issue":"19","key":"2023111414505481600_bib3","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1182\/blood-2014-05-577825","article-title":"Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis","volume":"124","author":"Chakraborty","year":"2014","journal-title":"Blood"},{"issue":"12","key":"2023111414505481600_bib4","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/s41591-019-0653-6","article-title":"Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms","volume":"25","author":"Durham","year":"2019","journal-title":"Nat Med"},{"issue":"22","key":"2023111414505481600_bib5","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1182\/blood-2016-01-690636","article-title":"Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages","volume":"127","author":"Emile","year":"2016","journal-title":"Blood"},{"key":"2023111414505481600_bib6","doi-asserted-by":"crossref","first-page":"107032","DOI":"10.1016\/j.leukres.2023.107032","article-title":"Spectrum of second primary malignancies and cause-specific mortality in pediatric and adult Langerhans cell histiocytosis","volume":"126","author":"Goyal","year":"2023","journal-title":"Leuk Res"},{"issue":"5","key":"2023111414505481600_bib7","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/bjh.18459","article-title":"Incidence, prevalence and survival in patients with Langerhans cell histiocytosis: a national registry study from England, 2013-2019","volume":"199","author":"Liu","year":"2022","journal-title":"Br J Haematol"},{"issue":"16","key":"2023111414505481600_bib8","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1016\/S0959-8049(03)00672-5","article-title":"Langerhans cell histiocytosis in adults. Report from the International Registry of the Histiocyte Society","volume":"39","author":"Arico","year":"2003","journal-title":"Eur J Cancer"},{"issue":"2","key":"2023111414505481600_bib9","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/ajh.26412","article-title":"Treatment outcomes and prognostic factors of patients with adult Langerhans cell histiocytosis","volume":"97","author":"Cao","year":"2022","journal-title":"Am J Hematol"},{"issue":"7749","key":"2023111414505481600_bib10","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41586-019-1012-y","article-title":"Efficacy of MEK inhibition in patients with histiocytic neoplasms","volume":"567","author":"Diamond","year":"2019","journal-title":"Nature"},{"issue":"3","key":"2023111414505481600_bib11","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/jamaoncol.2017.5029","article-title":"Vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET study","volume":"4","author":"Diamond","year":"2018","journal-title":"JAMA Oncol"},{"issue":"12","key":"2023111414505481600_bib12","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/onco.13541","article-title":"Efficacy of BRAF-inhibitor therapy in BRAF(V600E) -mutated adult langerhans cell histiocytosis","volume":"25","author":"Hazim","year":"2020","journal-title":"Oncol"},{"key":"2023111414505481600_bib13","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ejca.2022.03.036","article-title":"Langerhans cell histiocytosis and associated malignancies: a retrospective analysis of 270 patients","volume":"172","author":"Bagnasco","year":"2022","journal-title":"Eur J Cancer"},{"issue":"4","key":"2023111414505481600_bib14","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/bjh.14818","article-title":"Adult disseminated Langerhans cell histiocytosis: incidence, racial disparities and long-term outcomes","volume":"182","author":"Goyal","year":"2018","journal-title":"Br J Haematol"},{"key":"2023111414505481600_bib15","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1750-1172-8-72","article-title":"Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net","volume":"8","author":"Girschikofsky","year":"2013","journal-title":"Orphanet J Rare Dis"},{"issue":"25","key":"2023111414505481600_bib16","doi-asserted-by":"crossref","first-page":"5006","DOI":"10.1182\/blood-2012-09-455774","article-title":"Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis","volume":"121","author":"Gadner","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2023111414505481600_bib17","doi-asserted-by":"crossref","first-page":"e26784","DOI":"10.1002\/pbc.26784","article-title":"Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: current views and new vistas","volume":"65","author":"Yeh","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"2023111414505481600_bib18","unstructured":"Centers for Disease Control and Prevention\n          . Data access--compressed mortality file. 2018. https:\/\/www.cdc.gov\/nchs\/data_access\/cmf.htm."},{"issue":"2","key":"2023111414505481600_bib19","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/oxfordjournals.aje.a113306","article-title":"A\u00a0shortcut method for calculating the 95 per cent confidence interval of the standardized mortality ratio","volume":"115","author":"Vandenbroucke","year":"1982","journal-title":"Am J Epidemiol"},{"issue":"12","key":"2023111414505481600_bib20","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1002\/ajh.26355","article-title":"Langerhans cell histiocytosis with lung involvement in isolation and multisystem disease: staging, natural history, and comparative survival","volume":"96","author":"Hazim","year":"2021","journal-title":"Am J Hematol"},{"issue":"6","key":"2023111414505481600_bib21","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41408-022-00685-7","article-title":"Clinical features and outcomes of non-pulmonary unifocal adult Langerhans cell histiocytosis","volume":"12","author":"Hu","year":"2022","journal-title":"Blood Cancer J"},{"issue":"2","key":"2023111414505481600_bib22","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/mpo.2950230204","article-title":"Acute leukemia in association with Langerhans cell histiocytosis","volume":"23","author":"Egeler","year":"1994","journal-title":"Med Pediatr Oncol"},{"issue":"12","key":"2023111414505481600_bib23","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1002\/1097-0142(19931215)72:12<3723::AID-CNCR2820721226>3.0.CO;2-Y","article-title":"Acute promyelocytic leukemia with t(15;17) abnormality after chemotherapy containing etoposide for Langerhans cell histiocytosis","volume":"72","author":"Horibe","year":"1993","journal-title":"Cancer"},{"issue":"1","key":"2023111414505481600_bib24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/(SICI)1097-0215(19970328)71:1<9::AID-IJC3>3.0.CO;2-Y","article-title":"Risk of secondary leukemia after treatment with etoposide (VP-16) for Langerhans' cell histiocytosis in Italian and Austrian-German populations","volume":"71","author":"Haupt","year":"1997","journal-title":"Int J Cancer"},{"issue":"2","key":"2023111414505481600_bib25","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1111\/bjh.16177","article-title":"Concomitant Erdheim-Chester disease and chronic myelomonocytic leukaemia: genomic insights into a common clonal origin","volume":"187","author":"Goyal","year":"2019","journal-title":"Br J Haematol"},{"issue":"2","key":"2023111414505481600_bib26","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.3324\/haematol.2019.234187","article-title":"Bone marrow findings in Erdheim-Chester disease: increased prevalence of chronic myeloid neoplasms","volume":"105","author":"Goyal","year":"2020","journal-title":"Haematologica"},{"issue":"8","key":"2023111414505481600_bib27","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1182\/blood-2017-01-761718","article-title":"High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis","volume":"130","author":"Papo","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2023111414505481600_bib28","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1200\/JCO.2003.05.093","article-title":"Extended follow-up of patients with hairy cell leukemia after treatment with cladribine","volume":"21","author":"Goodman","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2023111414505481600_bib29","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1182\/blood.V92.6.1918","article-title":"Long-term follow-up of patients with hairy cell leukemia after cladribine treatment","volume":"92","author":"Saven","year":"1998","journal-title":"Blood"},{"key":"2023111414505481600_bib37","doi-asserted-by":"crossref","unstructured":"Acosta-Medina\n              AA\n            , KempsPG, ZondagTC, . BRAF V600E is associated with higher incidence of second cancers in adults with Langerhans cell histiocytosis. [published online ahead of print 18 August 2023]. Blood. http:\/\/doi.org\/10.1182\/blood.2023021212.","DOI":"10.1182\/blood.2023021212"},{"issue":"5","key":"2023111414505481600_bib30","doi-asserted-by":"crossref","first-page":"2101017","DOI":"10.1183\/13993003.01017-2021","article-title":"Long-term outcomes of adult pulmonary Langerhans cell histiocytosis: a prospective cohort","volume":"59","author":"Benattia","year":"2022","journal-title":"Eur Respir J"},{"issue":"1","key":"2023111414505481600_bib31","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/cam4.1844","article-title":"Langerhans cell histiocytosis in adults is associated with a high prevalence of hematologic and solid malignancies","volume":"8","author":"Ma","year":"2019","journal-title":"Cancer Med"},{"issue":"7","key":"2023111414505481600_bib32","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1056\/NEJMoa012087","article-title":"Clinical outcomes of pulmonary Langerhans'-cell histiocytosis in adults","volume":"346","author":"Vassallo","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2023111414505481600_bib33","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1182\/blood.2020005101","article-title":"High frequency of clonal hematopoiesis in Erdheim-Chester disease","volume":"137","author":"Cohen Aubart","year":"2021","journal-title":"Blood"},{"issue":"4","key":"2023111414505481600_bib34","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1182\/blood.2020008965","article-title":"CHIPping away at Erdheim-Chester disease","volume":"137","author":"Goyal","year":"2021","journal-title":"Blood"},{"issue":"9","key":"2023111414505481600_bib35","doi-asserted-by":"crossref","first-page":"E235","DOI":"10.1002\/ajh.25864","article-title":"Methotrexate and cytarabine for adult patients with newly diagnosed Langerhans cell histiocytosis: a single arm, single center, prospective phase 2 study","volume":"95","author":"Cao","year":"2020","journal-title":"Am J Hematol"},{"issue":"25","key":"2023111414505481600_bib36","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1200\/JCO.2015.65.9508","article-title":"BRAF mutation correlates with high-risk langerhans cell histiocytosis and increased resistance to first-line therapy","volume":"34","author":"Heritier","year":"2016","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/21\/6568\/2089019\/blooda_adv-2023-010706-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/21\/6568\/2089019\/blooda_adv-2023-010706-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T09:52:08Z","timestamp":1699955528000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/21\/6568\/497845\/Long-term-outcomes-among-adults-with-Langerhans"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,30]]},"references-count":37,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2023,11,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010706","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,30]]}}}